Advances in radiation therapy of head and neck cancer

Expert Review of Anticancer Therapy

Volumn 8, Issue 4, 2008, Pages 633-644

  Popovtzer, Aron ^a   Eisbruch, Avraham ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Biomarkers; Chemoradiation; CTV; GTV; Head and neck cancer; IMRT; Organs of risk; Targeted therapy

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; DOCETAXEL; FLUORODEOXYGLUCOSE; FLUOROURACIL; GEFITINIB; IMC 225; PACLITAXEL; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; RADIOSENSITIZING AGENT; TUMOR MARKER;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; EXTERNAL BEAM RADIOTHERAPY; HEAD AND NECK CANCER; HEAD AND NECK SURGERY; HUMAN; HYPOPHARYNX CANCER; INTENSITY MODULATED RADIATION THERAPY; INTERMETHOD COMPARISON; ION THERAPY; LARYNX CANCER; MONOTHERAPY; NASOPHARYNX CANCER; NEUTRON THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; OROPHARYNX CANCER; OVERALL SURVIVAL; PARANASAL SINUS CANCER; POSITRON EMISSION TOMOGRAPHY; POSTOPERATIVE CARE; PROTON THERAPY; QUALITY OF LIFE; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION EXPOSURE; RADIATION INJURY; RADIOSENSITIVITY; REVIEW; RISK REDUCTION; SKIN TOXICITY; SURVIVAL RATE; TREATMENT PLANNING; TREATMENT RESPONSE; UNITED STATES; HEAD AND NECK TUMOR; MULTIMODALITY CANCER THERAPY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; RADIATION-SENSITIZING AGENTS; TUMOR MARKERS, BIOLOGICAL;

EID: 43049179752     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/14737140.8.4.633     Document Type: Review

References (67)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2007. CA Cancer J. Clin. 57, 43-66 (2007).
2. Spitz MR. Epidemiology and risk factors for head and neck cancer. Semin. Oncol. 21, 281-288 (1994).
3. Maier H, De Vries N, Snow GB. Occupational factors in the aetiology of head and neck cancer. Clin. Otolaryngol. Allied Sci. 16, 406-412 (1991).
4. Atula S, Auvinen E, Grenman R et al. Human papillomavirus and Epstein-Barr virus in epithelial carcinomas of the head and neck region. Anticancer Res. 17, 4427-4433 (1997).
5. Mork J, Lie K, Glattre E et al. Human papilloma virus infection as a risk factor for squamous cell carcinoma of the head and neck. N. Engl. J. Med. 344, 1125-1131 (2001).
6. Gillison ML, Koch WM, Capone RB et al. Evidence for a causal association between human Papillomavirus and a subset of head and neck cancers. J. Natl Cancer Inst. 92, 709-720 (2000).
7. D'Souza G, Kreimer, AR, Viscidi R et al. Case control study human papillomavirus and oropharyngeal cancer. N. Engl. J. Med. 356, 1944-1956 (2007).
8. Fakhry C, Westra W, Li S et al. Prognostic significance of human papillomavirus (HPV) tumor status for patients with head and neck squamous cell carcinoma (HNSCC) in a prospective, multicenter Phase II clinical trial. J. Clin. Oncol. 25(18 Suppl.) (2007) (Abstract 6000).
9. Ritchie JM, Smith EM, Summersgill KF et al. Human papillomavirus infection as prognostic factor in carcinomas of the oral cavity and oropharynx. Int. J. Cancer 104, 336-344 (2003).
10. Pignon JP, Bourhis J, Domenge C, Designé L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-Analysis of Chemotherapy on Head and Neck Cancer. Lancet 355, 949-955 (2000).
11. Roa WH, Hazuka MB, Sandier HM et al. Results of primary and adjuvant CT-based 3-dimensional radiotherapy for malignant tumors of the paranasal sinuses. Int. J. Rad. Oncol. Biol. Phys. 28, 857-865 (1994).
12. Som PM. The present controversy over the imaging method of choice for evaluating the soft tissues of the neck. AJNR Am. J. Neuroradiol. 18, 1869-1872 (1997).
13. Schechter NR, Gillenwater AM, Byers RM et al. Can positron emission tomography improve the quality of care for head and neck cancer patients? Int. J. Rad. Oncol. Biol Phys. 51, 4-9 (2001).
14. Rouviere H. Lymphatic systems of the head and neck. Tobias MJ (Ed.). Edwards Brothers, Ann Arbor, MI, USA (1938).
15. Mukherji SK, Armao D, Joshi VM. Cervical nodal metastases in squamous cell carcinma of the head and neck: what to expert. Head Neck 23, 995-1005 (2001).
16. Robbins KT, Medina JE, Wolfe GT et al. Standardizing neck dissection terminology. Official report of the Academy's committee for head and neck surgery and oncology. Arch. Otolaryngol. Head Neck Surg. 117, 601-605 (1991).
17. Mohan R, Wu Q Manning M, Schmidt-Ullrich R. Radiobiological considerations in the design of fractionation strategies for intensity modulated radiation therapy of the head and neck. Int. J. Rad. Oncol. Biol. Phys. 46, 619-630 (2000).
18. De Neve W, De Gersem W, Derycke S. Clinical delivery of IMRT for relapsed or second-primary head and neck cancer using a multileaf collimator with dynamic control. Radiother. Oncol. 50, 301-314 (1999).
19. Xia P, Fu K, Wong GW et al. Comparison of treatment plans involving intensity-modulated radiotherapy for nasopharyngeal carcinoma. Int. J. Rad. Oncol. Biol. Phys. 48, 329-337 (2000).
20. Kam MK, Leung SF, Zee B et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J. Clin. Oncol. 25 (31), 4873-4879 (2001).
21. Pow EHN, Kwong DLW, McMillan AS et al. Xerostomia and quality of life after intensity modulated radiotherapy vs conventional radiotherapy for early stage nasopharyngeal carcinoma: Initial report on a randomized controlled trial. Int. J. Radiat. Oncol Biol. Phys. 66, 981-991 (2006).
22. Sultanem K, Shu HK, Xia P et al. Three-dimensional intensity-modulated radiotherapy in the treatment of nasopharyngeal. carcinoma: the University of California-San Francisco experience. Int. J Rad Oncol. Biol. Phys. 48, 711-722 (2000).
23. Lu TX Mai WY, Teh BS et al. Initial experience using intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma. Int. J. Radiat. Oncol. Biol Phys. 58, 682-687 (2004).
24. Adams E, Nutting CM, Convey DJ et al. Potential role of intensity modulated radiotherapy in the treatment of tumors of the maxillary sinus. Int. J. Rad. Oncol. Biol. Phys. 51, 579-588 (2001).
25. Tsien C, Eisbruch A, McShan R, Fraas B. IMRT for locally advanced paranasal sinus cancer: application of clinical decisions in the planning process. Int. J. Rad, Oncol. Biol Phys. 55, 776-784 (2003).
26. De Arruda FF, Puri DR, Zhung J et al. Intensity-modulated radiation therapy for the treatment of oropharyngeal carcinoma: The Memorial Sloan-Kettering Cancer Center experience. Int. J. Radiat. Oncol. Biol. Phys. 66, 966 (2006).
27. Feng M, Jabbari S, Lin A et al. Predictive factors of local-regional recurrences following IMRT of head and neck cancer. Radiother. Oncol. 77, 32-38 (2005).
28. Hodge C, Bentzen S, Wong G et al. Are we influencing outcome in oropharynx cancer with intensity-modulated radiotherapy? An inter-era comparison. Int. J. Radiat. Oncol. Biol. Phys. 69(4), 1032-1041 (2007).
29. Chao KS, Ozyigit G, Tran BN et al. Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 55, 312-321 (2003).
30. Clark CH, Bidmead AM, Nutting CM et al. Intensity-modulated radiotherapy improves target coverage, spinal cord sparing and allows dose escalation in patients with locally advanced cancer of the larynx. Radiother. Oncol. 70, 189-198 (2004).
31. Braaksma MM, Wijers OB, Levendag PC et al. Optimisation of conformal radiation therapy by intensity modulation: cancer of the larynx and salivary gland function. Radiother. Oncol. 66, 291-302 (2003).
32. Penagaricano JA, Ratanatharathorn V, Papanikolaou N et al. Intensity-modulated radiation therapy reduces the dose to normal tissue in T2N0M0 squamous cell carcinoma of the glottic larynx. Med. Dosim. 29, 254-257 (2004).
33. Eisbruch A, Marsh LH, Dawson LA et al. Recurrences near the base of the skull following IMRT of head and neck cancer: implications for target delineation in the high neck, and for parotid sparing. Int. J. Radiat. Oncol. Biol. Phys. 59, 28-42 (2004).
34. Chao KS, Ozyigit G, Tran BN et al. Patterns of failure in patients receiving definitive and postoperative IMRT for head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 55, 312-321 (2003).
35. Lee N, O'Meara W, Chan K et al. Concurrent chemotherapy and intensity-modulated radiotherapy for locoregionally advanced laryngeal and hypopharyngeal cancers. J. Radiat. Oncol. Biol. Phys. 69(2), 459-468 (2007).
36. Eisbruch A, Ten Haken R, Kim HM, Marsh L, Ship JA. Dose, volume and function relationships in parotid glands following conformal and intensity modulated irradiation of head and neck cancer. Int. J. Rad. Oncol. Biol. Phys. 45, 577-587 (1999).
37. Blanco A, Chao K, El Naqa I. Dose-volume modeling of salivary function in patients with head-and-neck cancer receiving radiotherapy. J. Radiat. Oncol. Biol. Phys. 62(4), 1055-1069 (2007).
38. Eisbruch A, Schwartz M, Rasch C et al. Dysphagia and aspiration after chemoradiotherapy for head-and-neck cancer: which anatomic structures are affected and can they be spared by IMRT? Int. J. Rad. Oncol. Biol. Phys. 60, 1425-1439 (2004).
39. Feng F, Kim H, Lyden T et al. Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures. Int. J. Rad. Oncol. Biol. Phs. 68(5), 1289-1298 (2006).
40. Yeung AR, Malyapa RS, Mendenhall WM et al. Dosimetric comparison of IMRT and proton therapy for head and neck tumors. Int. J. Radiat. Oncol. Biol. Phys. 66, S412 (2004).
41. Liebsch NJ, Truong M, Lopes W et al. Conformal Proton Radiotherapy for Primary Sphenoid Sinus Malignancies. Int. J. Radiat. Oncol. Biol. Phys. 66, S419 (2006).
42. Mizoe JE, Tsujii H, Kamada T et al. Dose escalation study of carbon ion radiotherapy for locally advanced head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 60, 358-364 (2004).
43. Laramore GE, Krall JM, Griffin TW et al. Neutron versus photon irradiation for unresectable salivary gland tumors: final report of an RTOG-MRC randomized clinical trial. Radiation Therapy Oncology Group. Medical Research Council. Int. J. Radiat. Oncol. Biol. Phys. 27, 235-240 (1993).
44. Barker JL Jr, Garden AS, Ang KK et al. Quantification of volumetric and geometric changes occurring during fractionated radiotherapy for head-and-neck cancer using an integrated CT/linear accelerator system. Int. J. Radiat. Oncol. Biol Phys. 59, 960-970 (2004).
45. Pignon JP, La Maître A, Bourhis J. Meta-analyses of chemotherapy in head and neck cancer (MACH-NC): an update. J. Radiat. Oncol. Biol. Phys. 69(2 Suppl.) S112-S114 (2007).
46. Hitt R, Lopez-Pousa A, Martinez J et al. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer. J. clin. Oncol. 23, 8636-8645 (2005).
47. Posner MR, Haddad RI, Wirth L et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N. Engl. J. Med. 357(17), 1705-1715 (2007).
48. Vermorken JB, Remenar E, Herpen CV et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N. Engl. J. Med. 357(17), 1695-1704 (2007).
49. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N. Engl. J. Med. 324, 1685-1690 (1991).
50. Forastiere AA, Goepfert H, Maor M et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N. Engl. J. Med. 349, 2091-2098 (2003).
51. Forastiere AA, Maor M, Weber RS et al. Long-term results of Intergroup RTOG 91-11, a Phase III trial to preserve the larynx-induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy (abstract). J. Clin. Oncol. 24, S284 (1991).
52. Al-Sarraf M, LeBlanc M, Giri PG et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized ntergroup study 0099. J. Clin. Oncol. 16, 1310-1317 (1998).
53. Al-Sarraf M, LeBlanc M, Giri P et al. Superiority of five year survival with chemo-radiotherapy vs radiotherapy in patients with locally advanced nasopharyngeal cancer. Intergroup (0099) (SWOG 8892, RTOG 8817, ECOG 2388) Phase III study. Final Report (abstract). Proc. Am. Soc. Clin. Oncol. 20, A227 (2001).
54. Bernier J, Domenge C, Ozsahin M et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N. Engl. J. Med. 350, 1945-1952 (2004).
55. Cooper JS, Pajak TF, Forastiere AA et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 350, 1937-1944 (2004).
56. Bernier J, Cooper JS, Pajak TF et al. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (22931) and RTOG (9501). Head Neck 27, 843-850 (2005).
57. Bonner JA, Harari PM, Giralt J et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N. Engl. J. Med. 354, 567-568 (2006).
58. Pfister DG, Su YB, Kraus DH et al. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot Phase II study of a new combined-modality paradigm. J. Clin. Oncol. 24, 1072-1078 (2006).
59. Vermorken JB, Mesia R, Vega V et al. Cetuximab extends survival of patients with recurrent or metastatic SCCHN when added to first line platinum based therapy - results of a randomized Phase III (Extreme) study. J. Clin. Oncol. 25(18 Suppl.) (2007) (Abstract 6091).
60. Trigo J, Hitt R, Koralewski P et al. Cetuximab monotherapy is active in patients (pts) with platinum-refractory recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN): results of a Phase II study. J. Clin. Oncol. 22(14 Suppl.) (2004) (Abstract 5502).
61. Baselga J, Trigo JM, Bourhis J et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J. Clin. Oncol. 23, 5568-5577 (2005).
62. Sieser PM, Hanks SK. The signaling and biological implications of FAK overexpression in cancer. Clin. Cancer Res. 12, 3233-3237 (2006).
63. Canal M, Secade P, Rodrigo JP et al. Overexpression of focal adhesion kinase in head and neck squamous cell carcinoma is independent of FAK gene copy number. Clin. Cancer Res. 12, 3272-3279 (2006).
64. Chen C, Kane M Song J et al. Phase I trial of gefitinib in combination with radiation or chemoradiation for patients with locally advanced squamous cell head and neck cancer. J. Clin. Oncol. 25(31), 4880-4886 (2007).
65. Kumar B, Cordell K, Lee J et al. Response to therapy and outcomes in oropharyngeal cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor, gender, and smoking. Int. J. Radiat. Oncol. Biol. Phys. 69(2), S109-S111 (2007).
66. Park W, Owens JM. Future directions in the treatment of oral cancer. Otolaryngol. Clin North Am. 39(2), 381-396 (2006).
67. Eisbruch A. IMRT for head and neck cancer. In: Head and Neck Cancer: a Multidisciplinary Approach (2nd Edition). Harrison LB, Session RB, Hong WK (Eds). Lippincott Williams & Wilkins, PA, USA 105-114 (2004).